Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions
US8021833B2 · kind B2 · utility
1Cited by
8References
3Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 12, 2004 |
| Grant date | Sep 20, 2011 |
| Priority date | — |
| Expiry date | Jul 15, 2026 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The importance of interaction between TSG101 and Vps28 in the release of HIV-1 and other viruses is disclosed. Suppressing or interfering in this interaction may inhibit HIV-1 virion release from infected cells. Agents that modulate this interaction include antibodies that bind to Vps28, polypeptides that bind to Vps28, and nucleic acids that may be used in gene therapy to interfere with the expression of wild type Vps28. Administration of such agents in vitro for screening and diagnostic purposes, and in vivo for diagnostic and therapeutic purposes, is disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.